Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Recent randomized trials have compared the newer antidiabetic agents to treatments involving sulfonylureas, drugs associated with increased cardiovascular risks and mortality in some observational studies with conflicting results. We reviewed the methodology of these observational studies by searching MEDLINE from inception to December 2015 for all studies of the association between sulfonylureas and cardiovascular events or mortality. Each study was appraised with respect to the comparator, the outcome, and study design–related sources of bias. A meta-regression analysis was used to evaluate heterogeneity. A total of 19 studies were identified, of which six had no major design-related biases. Sulfonylureas were associated with an increased risk of cardiovascular events and mortality in five of these studies (relative risks 1.16–1.55). Overall, the 19 studies resulted in 36 relative risks as some studies assessed multiple outcomes or comparators. Of the 36 analyses, metformin was the comparator in 27 (75%) and death was the outcome in 24 (67%). The relative risk was higher by 13% when the comparator was metformin, by 20% when death was the outcome, and by 7% when the studies had design-related biases. The lowest predicted relative risk was for studies with no major bias, comparator other than metformin, and cardiovascular outcome (1.06 [95% CI 0.92–1.23]), whereas the highest was for studies with bias, metformin comparator, and mortality outcome (1.53 [95% CI 1.43–1.65]). In summary, sulfonylureas were associated with an increased risk of cardiovascular events and mortality in the majority of studies with no major design-related biases. Among studies with important biases, the association varied significantly with respect to the comparator, the outcome, and the type of bias. With the introduction of new antidiabetic drugs, the use of appropriate design and analytical tools will provide their more accurate cardiovascular safety assessment in the real-world setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, sulfonylureas which are the second most commonly used antidiabetic drug after metformin, have been shown to be associated with an increased risk of cardiovascular events and mortality [71].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [71]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“For instance, using as comparator thiazolidinediones, which have been associated with an increased risk of cardiovascular events (55), could lead to an underestimation of the association.”
MethodSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708 · cited 1×
“ple, the 1,443 patients excluded because they received insulin some time during follow-up had to be alive at the time that they received the insulin; such exclusions will introduce immortal time bias (56).”
BackgroundSelf-citationHuxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534 · cited 1×
“It is well established that type 2 diabetes is associated with an increased risk of cardiovascular morbidity and mortality (1).”
BackgroundOral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus
Krentz, A. J., & Bailey, C. J. (2005) · Drugs · doi:10.2165/00003495-200565030-00005 · Cited by 1,108 · cited 1×
“In addition to the methodological issues described above, it is important to recognize that there are differences in the pharmacodynamic and pharmacokinetic properties of the different sulfonylureas; these may have an impact on their association with cardiovascular outcomes (58).”
Background(1970) · PubMed · Cited by 976
Cited by
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312
“For example, sulfonylureas which are the second most commonly used antidiabetic drug after metformin, have been shown to be associated with an increased risk of cardiovascular events and mortality [71].”
BackgroundRSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“Further, sulfonylureas and meglitinides increase the risk of myocardial ischemic injury and may be associated with increased risk of cardiovascular events and mortality.[808] SGLT-2 inhibitors are associated with high risks for DKA and volume depletion.”
BackgroundDouros, A., Dell’Aniello, S., Yu, O. H. Y., Filion, K. B., Azoulay, L., & Suissa, S. (2018) · BMJ · doi:10.1136/bmj.k2693 · Cited by 135
Self-citationGenetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease
Goodarzi, M. O., & Rotter, J. I. (2020) · Circulation Research · doi:10.1161/circresaha.119.316065 · Cited by 141
Do sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
O’Brien, M. J., Karam, S. L., Wallia, A., Kang, R. H., Cooper, A. J., Lancki, N., Moran, M. R., Liss, D. T., Prospect, T. A., & Ackermann, R. T. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6125 · Cited by 113
Raparelli, V., Elharram, M., Moura, C. S., Abrahamowicz, M., Bernatsky, S., Behlouli, H., & Pilote, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012940 · Cited by 106
Lee, S., Zhou, J., Wong, W. T., Liu, T., Wu, W. K. K., Wong, I. C. K., Zhang, Q., & Tse, G. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00751-4 · Cited by 97
Douros, A., Yin, H., Yu, O. H. Y., Filion, K. B., Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc17-0595 · Cited by 109
“shortcomings, including exposure misclassification, time-lag bias, and selection bias (2).”
BackgroundSelf-citationPatorno, E., Schneeweiss, S., Gopalakrishnan, C., Martin, D., & Franklin, J. M. (2019) · Diabetes Care · doi:10.2337/dc19-0069 · Cited by 94
“Given that medications of both classes are frequently used as second-line therapy after metformin, and because sulfonylureas have been associated with concerns regarding their cardiovascular safety (10), the results of this trial could have a significant impact on clinical practice if practitioners conclude there is a…”
BackgroundAu Yeung, S. L., Luo, S., & Schooling, C. M. (2018) · Diabetes Care · doi:10.2337/dc18-0289 · Cited by 92
“Notably, some of the agents used to achieve glycemic control, such as sulphonylureas, have been implicated in CVD (13).”
BackgroundDrug‐induced peripheral oedema: An aetiology‐based review
Largeau, B., Cracowski, J., Lengellé, C., Sautenet, B., & Jonville‐Béra, A. ‐. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14752 · Cited by 95
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lopes, R. D., Al-Khalidi, H., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 79
Roumie, C. L., Chipman, J., Min, J. Y., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T., & Griffin, M. R. (2019) · JAMA · doi:10.1001/jama.2019.13206 · Cited by 76
Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 90
Conte, C., & Secchi, A. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1137-8 · Cited by 81
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 67
Post-Transplantation Diabetes Mellitus
Ahmed, S. H., Biddle, K., Augustine, T., & Azmi, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00790-5 · Cited by 77
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes
Preiser, J., Provenzano, B. C., Wasineeart, M., Halenarova, K. W., & Cnop, M. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003237 · Cited by 69
Colagiuri, S., Matthews, D. R., Leiter, L. A., Chan, S. P., Sesti, G., & Marre, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.028 · Cited by 63
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 65
Jensen, M. H., Kjølby, M., Hejlesen, O. K., Jakobsen, P. E., & Vestergaard, P. (2020) · Diabetes Care · doi:10.2337/dc19-2535 · Cited by 63
“Azoulay and Suissa (22) recently demonstrated that SUs are associated with increased cardiovascular events from a meta-regression analysis of observational studies, confirming the observation in this study.”
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Yandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1358064 · Cited by 50
“outcome increased the RR of CV events and mortality [47,48].”
BackgroundRecent advances in diabetes treatments and their perioperative implications
Kuzulugil, D., Papeix, G., Luu, J., & Kerridge, R. K. (2019) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000735 · Cited by 52
Filion, K. B., Douros, A., Azoulay, L., Yin, H., Yu, O. H. Y., & Suissa, S. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14056 · Cited by 50
“The cardiovascular effects of sulfonylureas in the specific setting of first‐line treatment with metformin as the comparator have also been examined in several observational studies, which have provided heterogeneous results.(7) However, many of these studies had important methodological limitations.”
BackgroundSelf-citationComparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Pedroso Camargos, A., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.069 · Cited by 47
Haye, A., Ansari, M. A., Rahman, S. O., Shamsi, Y., Ahmed, D., & Sharma, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173376 · Cited by 50
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Camargos, A. P., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · doi:10.1101/2024.02.05.24302354 · Cited by 46
Mannucci, E., Gallo, M., Giaccari, A., Candido, R., Pintaudi, B., Targher, G., Monami, M., & Diabetes, T. S. J. P. F. I. G. O. T. O. T. 2. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14888 · Cited by 43
“These results are in line with some previous analyses, reporting an increased risk of stroke in randomized trials,(54) and an increased risk of MACE in observational studies.(55) The”
ResultCarbone, S., Dixon, D. L., Buckley, L. F., & Abbate, A. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.018 · Cited by 45
“Subsequent meta-analyses in recent years using randomized clinical trial data or observational data have also found conflicting results.(47,48) The ongoing CAROLINA (Cardiovascular Outcome Trial of Linagliptin Versus Glimepiride in Type 2 Diabetes) study, which is comparing the CV safety of linagliptin to glimepiride,…”
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 57
Sodium glucose co-transporter 2 inhibitors and heart failure.
Ghosh, R. K., Ghosh, G. C., Gupta, M., Bandyopadhyay, D., Akhtar, T., Deedwania, P., Lavie, C. J., Fonarow, G. C., & Aneja, A. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.08.038 · Cited by 41
Sulphonylureas in the management of type 2 diabetes: To be or not to be?
Scheen, A. J. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100002 · Cited by 48
Zhou, J., Zhang, G., Chang, C., Chou, O. H. I., Lee, S., Leung, K. S. K., Wong, W. T., Liu, T., Wai, A. K. C., Cheng, S. H., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-021-01841-4 · Cited by 38
Sulfonylureas and Cardiovascular Safety: The Final Verdict?
Wexler, D. J. (2019) · JAMA · doi:10.1001/jama.2019.14533 · Cited by 37
Toxicity of Metformin and Hypoglycemic Therapies
Akhter, M. S., & Uppal, P. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.004 · Cited by 40
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.05.007 · Cited by 37
Eckstein, M. L., Williams, D. M., O'Neil, L., Hayes, J., Stephens, J. W., & Bracken, R. M. (2018) · Diabetic Medicine · doi:10.1111/dme.13865 · Cited by 45
“Sulfonylureas may impact on cardiovascular disease risk by influencing body mass, blood 296 pressure and lipid metabolism (48).”
BackgroundArvanitakis, K., Koufakis, T., Kalopitas, G., Papadakos, S. P., Kotsa, K., & Germanidis, G. S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102935 · Cited by 35
Galindo, R. J., Dhatariya, K., Peralta, F. G., & Umpierrez, G. E. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01464-1 · Cited by 36
Wang, H., Cordiner, R. L. M., Huang, Y., Donnelly, L. A., Hapca, S. M., Collier, A., McKnight, J. A., Kennon, B., Gibb, F. W., McKeigue, P., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1238 · Cited by 35
“A meta-analysis of 44 observational studies assessing the CV safety of SU reported several likely sources of bias such as using selected populations with CV complications, performing within-class comparisons, or utilizing a normal glucose tolerance cohort as comparator (10).”
MethodKhunti, K., Hassanein, M. M., Lee, M., Mohan, V., & Amod, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00833-x · Cited by 38
“The risk of CVD seen with sulfonylureas in some observational studies [38, 39] has not been demonstrated in randomised controlled trials (RCTs), including the TOSCA-IT, CAROLINA, ADVANCE and ADOPT studies [40–43].”
BackgroundGlibenclamide alleviates β adrenergic receptor activation-induced cardiac inflammation
Cao, N., Wang, J.-J., Wu, J., Xu, W., Wang, R., Chen, X.-D., Feng, Y., Cong, W., Zhang, Y., Xiao, H., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00734-0 · Cited by 32
Mannucci, E., Monami, M., Candido, R., Pintaudi, B., & Targher, G. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.032 · Cited by 29
Scheen, A. J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101405 · Cited by 26
Modern Sulfonylureas: Dangerous or Wrongly Accused?
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dci17-0003 · Cited by 27
“To summarize, the main findings of Azoulay and Suissa (14) suggest that some of the harm attributed to sulfonylureas may be related to unintended bias in the design or interpretation of studies rather than an effect of this class of agents.”
BackgroundInfluentialWeng, W., Tian, Y., Kong, S. X., Ganguly, R., Hersloev, M., Brett, J., & Hobbs, T. M. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0090-y · Cited by 26
Pharmacological management of type 2 diabetes: what’s new in 2017?
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1376652 · Cited by 27
Stimulus-Secretion Coupling in Beta-Cells: From Basic to Bedside
Islam, M. S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12457-1_37 · Cited by 26
Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., et al. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115964 · Cited by 24
Triantafylidis, L. K., Hawley, C. E., Fagbote, C. O., Li, J., Genovese, N., & Paik, J. M. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019876499 · Cited by 22
The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?
Pop, L. M., & Lingvay, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0954-4 · Cited by 25
Emerging uncertainty on the anti-aging potential of metformin
Keys, M. T., Hallas, J., Miller, R. A., Suissa, S., & Christensen, K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102817 · Cited by 29
“…studies can replicate the findings of randomized intervention trials, by for example, using target trial emulation and new-user pharmacoepidemiologic study designs (Wang et al., 2023a; Hernán et al., 2022; Johnson et al., 2013; Suissa et al., 2017; Lund et al., 2015; Wintzell et al., 2022).”
InfluentialSelf-citationLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1193-3793 · Cited by 33
Lajara, R. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1670017 · Cited by 23
“contrast, other glucose-lowering therapies, including older agents in the sulfonylurea class (which may increase the risk of CV events and mortality) [24] and certain DPP-4is and insulin (which may”
BackgroundChallenges and Strategies for Diabetes Management in Community-Living Older Adults
Sinclair, A. J., & Abdelhafiz, A. H. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0013 · Cited by 23
Kant, R., Munir, K. M., Kaur, A., & Verma, V. K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i6.324 · Cited by 19
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2020
Orozco‐Beltrán, D., Cuixart, C. B., Sánchez, J. J. A., Banegas, J. R., Cuenca, A. M. C., Gil-Guillén, V. F., Rioboó, E. M., & Pérez, J. N. (2020) · Atención Primaria · doi:10.1016/j.aprim.2020.08.002 · Cited by 30
“…a favor En prevención secundaria (pacientes con evento cardiovascular), el fármaco de elección asociado a metformina será un ISGLT2 (empaglifozina, canaglifozina) o un arGLP1 (liraglutida, semaglutida, dulaglutida) asociado o no a cualquier otro antidiabético, salvo contraindicación o intolerancia”
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 23
“In some of these publications, SU do not seem to increase the number of coronary events, although they could increase the risk of strokes and have been associated with a significant increase in mortality [51,52].”
BackgroundChazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm
Riddle, M. C. (2019) · Diabetes Care · doi:10.2337/dci19-0034 · Cited by 21
The doubled burden of diabetic bone disease: hip fracture and post-hip fracture mortality
Behanová, M., Haschka, J., Zwerina, J., Wascher, T. C., Reichardt, B., Klaushofer, K., & Kocijan, R. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1155 · Cited by 19
Paridari, P., Jabermoradi, S., Gholamzadeh, R., Vazifekhah, S., Vazirizadeh-Mahabadi, M., Dizaji, S. R., Forouzannia, S. A., Hosseini, M., & Yousefifard, M. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102721 · Cited by 23
Update on Management of Type 2 Diabetes for Cardiologists
Qureshi, M., Gammoh, E., Shakil, J., & Robbins, R. J. (2018) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-14-4-273 · Cited by 19
Adeghate, E. A., Kalász, H., Jaberi, S. A., Adeghate, J. O., & Tekes, K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1865914 · Cited by 19
Keys, M. T., Thinggaard, M., Larsen, L. A., Pedersen, D. A., Hallas, J., & Christensen, K. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac200 · Cited by 16
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2022
Orozco‐Beltrán, D., Cuixart, C. B., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Rioboó, E. M., Baldó, A. J., Vicuña, J., & Pérez, J. N. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102444 · Cited by 80
Pharmacogenetics of Oral Antidiabetic Therapy
Ordelheide, A., de Angelis, M. H., Häring, H., & Staiger, H. (2018) · Pharmacogenomics · doi:10.2217/pgs-2017-0195 · Cited by 18
Komaru, Y., Takeuchi, T., Suzuki, L., Asano, T., & Urayama, K. Y. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107511 · Cited by 18
Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect
Suissa, S. (2018) · Diabetes Care · doi:10.2337/dc17-1059 · Cited by 16
“Second, in terms of the need for additional antidiabetes treatment, insulin and sulfonylureas have been associated with increased risks of death in several observational studies (15,16).”
BackgroundSelf-citationKadowaki, T., Wang, G., Rosenstock, J., Yabe, D., Peng, Y., Kanasaki, K., Mu, Y., Mattheus, M., Keller, A., Okamura, T., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00447-5 · Cited by 16
Baksh, S. N., McAdams‐DeMarco, M., Segal, J. B., & Alexander, G. C. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4437 · Cited by 17
Reducing the Burden of Mortality in Older People With Diabetes: A Review of Current Research
Forbes, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00133 · Cited by 20
Xu, Y., Wang, T., Yang, Z., Lin, H., Shen, P., & Zhan, S. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5024 · Cited by 17
“observational studies with no major biases, which restricted the cohort to patients newly treated monotherapy comparing sulfonlyurea to metformin, have suggested sulfonylurea has an increased cardiovascular risk associated with sulfonylurea.(24) However, the comparators used in these studies are mostly metformin excep…”
BackgroundResultWalczewska-Szewc, K., & Nowak, W. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c07292 · Cited by 13
The Role of Platelets in Hypoglycemia-Induced Cardiovascular Disease: A Review of the Literature
Ali, A. A. G., Niinuma, S. A., Moin, A. S. M., Atkin, S. L., & Butler, A. E. (2023) · Biomolecules · doi:10.3390/biom13020241 · Cited by 14
“In a methodological review of observational studies comparing sulfonylureas to metformin, time lag bias was cited as an important factor skewing the results of such studies [95].”
BackgroundDouros, A., Dell’Aniello, S., Yu, O. H. Y., & Suissa, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13893 · Cited by 13
Self-citationCieslik, L., Cresswell, N. R., Fineberg, D., Mariani, J. A., & Patel, H. C. (2020) · Internal Medicine Journal · doi:10.1111/imj.15137 · Cited by 14
Cordiner, R. L. M., & Pearson, E. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13596 · Cited by 14
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Baccetti, F., Crisafulli, C., Andreozzi, F., Mannino, G. C., Nicolucci, A., Michelli, A., Miranda, C., Candido, R., Bartolo, P. D., Cianni, G. D., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111781 · Cited by 17
Yandrapalli, S., Jolly, G. P., Horblitt, A. M., Pemmasani, G., Sanaani, A., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000308 · Cited by 14
“Interestingly, a recent metaregression analysis of 19 real-world observational studies showed that SUs were associated with an increased risk of CV events and mortality in 6 of the included studies with no major design-related biases.(94) But the results were skewed due to the presence of bias, selecting metformin as…”
BackgroundShariat‐Madar, Z., & Mahdi, F. (2025) · Molecules · doi:10.3390/molecules30224448 · Cited by 18
“…generally well-tolerated, sulfonylureas may elicit adverse effects, including microvascular complications [88], cardiovascular events and mortality [89], myocardial infarction [90], ventricular arrhythmias and sudden cardiac death [91], severe hypoglycemia, atherosclerosis, cardiovascular disease…”
Cheung, J. T. K., Yu, R., & Woo, J. (2020) · Family Practice · doi:10.1093/fampra/cmaa062 · Cited by 10
“For example, antidiabetic drugs, namely sulfonylureas, were associated with increased risks of cardiovascular events and mortality (14).”
BackgroundComoglio, R. H., & Vidal, X. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.11.002 · Cited by 13
Bagepally, B. S., Chaikledkaew, U., Youngkong, S., Anothaisintawee, T., Thavorncharoensap, M., Dejthevaporn, C., & Thakkinstian, A. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s328433 · Cited by 14
“The treatment failure is defined as T2DM patients unable to maintain glycemic control (HbA1C <7%) according to the ADA guidelines.(12) An annual discounting rate of 3% was applied to both costs and outcomes.”
BackgroundMethodInfluentialPazoki, M., Chichagi, F., Hadadi, A., Kafan, S., Montazeri, M., Kazemian, S., Aminorroaya, A., Ebrahimi, M., Ashraf, H., Hazaveh, M. M., et al. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00901-4 · Cited by 10
“In the pre-pandemic era, meta-regression analysis of the observational studies showed that sulfonylureas were associated with an increased risk of cardiovascular events and mortality in patients with DM [36].”
BackgroundPositioning Metabolism as a Central Player in the Diabetic Heart
Mereweather, L. J., Aparicio, C. N. M., & Heather, L. C. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.1.92 · Cited by 11
Khunti, K., HERTZ, C. L., Husemoen, L. L. N., Mocevic, E., Nordsborg, R. B., Piltoft, J. S., & Bain, S. C. (2021) · Diabetic Medicine · doi:10.1111/dme.14697 · Cited by 10
Abdelhamid, M., Alghalayini, K. W., Alhumood, K. A., Altun, B., Arafah, M., Bader, F. M., Ibrahim, M. F., Sabbour, H. M., Shawky, A., Skouri, H. N., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14456 · Cited by 10
Dinu, A., Confederat, L. G., Dragostin, I., Morariu, I. D., Tutunaru, D., & Dragostin, O.-M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090709 · Cited by 9
“In comparison to other modern drug classes, such as GLP-1 receptor agonists and SGLT2 inhibitors, older SU agents lack beneficial cardiovascular effects, meaning they do not reduce the risk of hypertension or myocardial infarction [76].”
Dalem, J. D. R.-V., Brouwers, M. C. G. J., Stehouwer, C. D. A., Krings, A., Klungel, O. H., Driessen, J. H. M., de Vries, F., & Burden, A. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13168 · Cited by 9
“As a result, we were able to take into account switching between different sulphonylureas or other treatments and avoid exposure misclassification that often arises if an intention-totreat approach is used.(20) Similarly, as detailed information was available on comorbidities and concomitant use of other drugs, we wer…”
BackgroundGlucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
Sečník, J., Xu, H., Schwertner, E., Hammar, N., Alvarsson, M., Winblad, B., Eriksdotter, M., Ptacek, S. G., & Religa, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215337 · Cited by 11
“Despite 572 some inconsistencies, sulfonylureas did not increase 573 all-cause mortality in the general type 2 diabetes pop574 ulation [8, 38] and the risk of bias among studies very 575 much depend on the comparator and the outcome 576 [39].”
BackgroundIto, H., Matsumoto, S., Izutsu, T., Kusano, E., Nishio, S., Antoku, S., Yamasaki, T., Mori, T., Togane, M., Ando, S., et al. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s221655 · Cited by 12
Koufakis, T., Dimitriadis, G., & Kotsa, K. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13035 · Cited by 10
“55).(19) However, a series of methodological issues, including “selection,” “treatment allocation,” and “time lag” biases, as well as exposure misclassification, render the analysis of the findings of observational studies, challenging.”
Deng, Y., Polley, E. C., Wallach, J. D., Herrin, J. S., Ross, J. S., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000419 · Cited by 10
“36 37 Previous studies also did not compare”
ResultRuiz‐García, A., Arranz-Martínez, E., Merchante, I. M., Fuster, V. P., Tamarit, J. J., Trias, F., Pintó, X., & Ascaso, J. F. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.006 · Cited by 14
Understanding the cardiovascular risk with non-insulin antidiabetic drugs
Athyros, V. G., Imprialos, K. P., Stavropoulos, K., Sahinidis, A., & Doumas, M. N. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1586881 · Cited by 10
Metadata
- Authors
- Azoulay, L., & Suissa, S.
- Affiliations
- Jewish General Hospital (CA)
- Corresponding author
- Azoulay, Laurent
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-04-12
- Volume
- 40
- Issue
- 5
- Pages
- 706-714
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2607457744
- Cited by
- 195
- References
- 75
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 17 · 2023: 17 · 2022: 18 · 2021: 27 · 2020: 34 · 2019: 25 · 2018: 26 · 2017: 10
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- sulfonylureas, cardiovascular events, mortality, metformin, bias in observational studies, antidiabetic drugs, cardiovascular safety, type 2 diabetes
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Regression Analysis, Risk Factors, Sulfonylurea Compounds, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.